Our recent preclinical studies in a mouse orthotopic 4T1 mammary tumor model have shown that microsphere vaccination with immunogenic MHC restricted survivin peptide epitopes and adjuvants significantly reduces tumor take and tumor growths rates [52], and support the concept of this generalized approach. Here, BIRC5 is linked to neoplasm.